Darren Braccia is Chief Business Officer, providing day-to-day support to the Myeloid CEO and leadership team, across strategic and operating business needs. Overall, he maintains the key functional role leading the business development strategy and its implementation, and he deploys regularly in response to the evolving operating needs of the business. Darren provides senior-level guidance to enhance internal decision making and execution. He brings a mindset of new products-for-patients, sooner and an appreciation for externalization to the internal teams. He works to identify, evaluate, and select optimal global partners for our assets. His external activities include cultivating collaborative discussions, structuring and negotiating the details of business relationships, and supporting the deal. He interfaces across the organization to provide guidance and support business decision making for our expanding portfolio of development candidates, RNA technologies, and capabilities.
Prior to joining Myeloid, Darren held progressive business development and leadership roles, always working in close daily collaboration with teams to discover, develop, and commercialize novel therapeutics (e.g., Vertex, across two distinct eras of its evolution to commercial success; Biogen and Lysosomal Therapeutics). He has also held business development and general management roles working on behalf of growth-capital private investors in the fields of clinical diagnostics, life science research platforms, and consumables (Magellan Biosciences). Darren’s past efforts have spanned research programs, development candidates, and registered products within the fields of oncology, cystic fibrosis and orphan diseases, inflammation, neurodegeneration, infectious diseases, and point-of-care pediatric diagnostics. His specific contributions to the broader objective of enhancing human health have included leading roles in structuring the financing of next-generation CFTR correctors, raising financial support for the development of a first-in-class small molecule to treat GBA1 Parkinson’s Disease (an orphan genetic form of PD), and executing an inorganic growth strategy by acquiring and integrating four companies at Magellan Biosciences, resulting in a sustainable EBITDA-positive enterprise with cash to innovate further.
Darren is a graduate of the J.L. Kellogg Graduate School of Management at Northwestern University and Washington and Lee University.